Optimization of individualized faricimab dosing for patients with diabetic macular edema: Protocol for the SWAN open-label, single-arm clinical trial
The SWAN trial is expected to provide evidence to support individualized faricimab dosing regimens, with the potential to reduce the burden of frequent treatments on patients, caregivers, and healthcare systems.
Authors
- Tomoaki Murakami (ORCID: https://orcid.org/0000-0002-0314-8807)
- Masahiko Shimura (ORCID: https://orcid.org/0000-0001-5456-6374)
- Masahiko Sugimoto (ORCID: https://orcid.org/0000-0001-5147-4183)
- Jun Tsujimura
- Keisuke Iwasaki
- Kiyoshi Suzuma
- Shintaro Nakao (ORCID: https://orcid.org/0000-0003-4200-0052)
- Takao Hirano (ORCID: https://orcid.org/0000-0003-3601-8053)
- Taiji Nagaoka (ORCID: https://orcid.org/0000-0003-3933-1002)
- Shigeo Yoshida (ORCID: https://orcid.org/0000-0003-1049-8909)
- Miho Nozaki (ORCID: https://orcid.org/0000-0003-4711-6994)
- Toshinori Murata (ORCID: https://orcid.org/0000-0001-6577-5032)
- Yoshihiro Takamura (ORCID: https://orcid.org/0000-0001-7334-2245)
Institutions
- Kurume University (JP)
- University of Fukui (JP)
- Yamagata University (JP)
- Shinshu University (JP)
- Asahikawa Medical University (JP)
- Kagawa University (JP)
- Kyoto University (JP)
- Nagoya City University (JP)
- Juntendo University (JP)
- Tokyo Medical University Hachioji Medical Center (JP)
Publication Details
- Journal
- PLoS ONE
- Published
- 2024-10-10
- DOI
- https://doi.org/10.1371/journal.pone.0311484
- Citations
- 3
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.62
Funders
- Chugai Pharmaceutical